Company: INDP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001641172-25-023490
Chunk: 12

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 12
---
 offerings:

| ● | common stock;                               |
| ● | preferred stock;                            |
| ● | subscription rights;                        |
| ● | debt securities;                            |
| ● | warrants;                                   |
| ● | units consisting of any                     
 combination of the securities listed above. |

In this prospectus, we refer to the common stock, preferred stock, subscription rights, debt securities, warrants and units collectively as “securities.” The total dollar amount of all securities that we may sell will not exceed $200,000,000.

If we issue debt securities at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount of the debt securities.

This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.

| 7 |

<div align='center'>DESCRIPTION OF CAPITAL STOCK</div>

This section describes the general terms and provisions of the shares of our common stock, par value $0.01 per share, and preferred stock, par value $0.01 per share, and some of the provisions of our certificate of incorporation and bylaws and of the Delaware General Corporation Law, or DGCL. This description is only a summary. Our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws have been filed as exhibits to our periodic reports filed with the SEC, which are incorporated by reference in this prospectus. You should read our amended and restated certificate of incorporation and our amended and restated bylaws for additional information before you buy any of our common stock, preferred stock or other securities. See “Where You Can Find More Information.”

General

The following description of our capital stock is a summary. This summary is subject to the General Corporation Law of Delaware, or the DGCL, and the complete text of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws.

Our authorized capital stock consists of shares made up of 200,000,000 shares of common stock, par value $0.01 per share and 5,000,000 shares of undesignated preferred stock, par value $0.01 per share.

Reverse Stock Split

We implemented a 1-for-28 reverse stock split of our outstanding common stock, which became effective on June 26, 2025 with the shares began trading on a post-split